Abstract
Acute single-dose response of drug-induced parkinsonism (DIP) to L-Dopa and apomorphine challenge was evaluated in a double-blind crossover study in 12 schizophrenic patients. There were two noteworthy negative findings. First, neither L-Dopa nor apomorphine produced significant improvements in DIP and second, no changes (neither improvement nor worsening) were found in patients' psychiatric status. Findings suggest that, for a stimulation dose reaching almost 90% of the responsive dose for idiopathic Parkinson's disease, no significant changes may reasonably be expected in the parkinsonism of schizophrenic patients treated with neuroleptic drugs.
Publication types
-
Clinical Trial
-
Controlled Clinical Trial
MeSH terms
-
Adult
-
Analysis of Variance
-
Antiparkinson Agents / therapeutic use*
-
Antipsychotic Agents / adverse effects
-
Apomorphine / therapeutic use*
-
Cross-Over Studies
-
Double-Blind Method
-
Female
-
Humans
-
Levodopa / therapeutic use*
-
Motor Activity / drug effects*
-
Parkinson Disease, Secondary / drug therapy*
-
Parkinson Disease, Secondary / etiology*
-
Parkinson Disease, Secondary / physiopathology
-
Psychiatric Status Rating Scales
-
Schizophrenia / chemically induced*
-
Schizophrenia / drug therapy*
-
Schizophrenia / physiopathology
Substances
-
Antiparkinson Agents
-
Antipsychotic Agents
-
Levodopa
-
Apomorphine